Aims: Biodegradable polymer drug-eluting stents (BP-DES) were developed in hopes of reducing the risk of stent thrombosis. The comparison of this new stent platform with second-generation durable polymer drug-eluting stents (DP-DES) has not been well described. We, therefore, performed a meta-analysis to evaluate the safety and efficacy profiles of BP-DES versus second-generation DP-DES in patients with coronary artery disease.
| INTRODUCTION
Drug-eluting stents (DES) have revolutionized the treatment of coronary artery disease in patients undergoing percutaneous coronary intervention (PCI). Advances in coronary stent technology have continually improved on patient outcomes through the refinement of design and component materials. 1 These sequential stent platforms have included bare metal stents (BMS), durable polymer drug-eluting stents (DP-DES), and biodegradable polymer drug-eluting stents (BP-DES). The first generation of DP-DES were introduced to reduce the risk of in-stent restenosis and subsequent target lesion revascularization associated with BMS. 2 However, first-generation DP-DES were found to have an increased risk of very late stent thrombosis (> 12 months) compared with BMS. 3 This adverse event has been related to polymer-induced hypersensitivity reaction, incomplete strut re-endothelialization, stent malapposition, and accelerated neoatherosclerosis. 4 Consequently, a second generation of DP-DES were developed, with novel anti-proliferative drugs, more biocompatible polymer coatings, and thinner metal alloy struts made possible by the use of cobalt-chromium or platinum-chromium in place of stainless steel. 5 Second-generation DP-DES were shown to reduce the risk of very late stent thrombosis associated with first-generation DP-DES. 6 However, concerns regarding the potential thrombogenicity of the durable polymer coating have remained, resulting in recommendations for dual antiplatelet agents to be continued for longer periods following DP-DES implantation. 7 BP-DES were developed in the hope of providing a similar safety profile to that of BMS (reduced risk of stent thrombosis), while maintaining the efficacy profile of DP-DES (reduced risk of target lesion revascularization). The polymer coating of BP-DES degrades over two to nine months, and simultaneously releases controlled amounts of the anti-proliferative drug. 8 The proposed benefit of BP-DES is the eventual absence of a foreign material in the vessel wall, in which there is a lower possibility for residual inflammation and, therefore, a reduced risk of very late stent thrombosis. 9 There have been suggestions that BP-DES require a shorter duration of dual antiplatelet therapy (DAPT) than DP-DES. 10 It is important to ensure that any potential safety benefits are not offset by the loss of efficacy (prevention of restenosis) through changes to the elution profile of the drug.
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Therefore, we performed a meta-analysis of randomized controlled trial published to date to gain an evidence-based understanding of the safety and efficacy profiles of BP-DES versus second-generation DP-DES.
| METHODS

| Search strategy
Our meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 12 We conducted electronic database searches using Ovid Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), American College of Physicians (ACP) Journal Club, and Database of Abstracts of Reviews of Effectiveness (DARE) from their dates of inception to June 2018. To identify potentially relevant studies, we used the following keywords or MeSH terms: "randomized controlled trial", "drug-eluting stent", "durable polymer", "permanent polymer", "everolimus-eluting stent", "zotarolimus-eluting stent", "biodegradable polymer", "bioabsorbable polymer", "bioresorbable polymer", "biolimus-eluting stent", "sirolimuseluting stent", and "stent thrombosis". The reference lists of retrieved articles were evaluated using the inclusion and exclusion criteria.
| Selection criteria
The present meta-analysis included studies that had a randomized design. We included studies comparing patients with either BP-DES or second-generation DP-DES ( Table 1 ). The BP-DES included biolimus-, everolimus-, and sirolimus-eluting stents. The second-generation DP-DES included everolimus-and zotarolimus-eluting stents.
Studies evaluating sirolimus-and paclitaxel-eluting stents were not included, as these are first-generation DP-DES. For duplicate studies, only the most recent reports with greatest number of patients and length of follow-up were included for quantitative assessment. We limited the electronic database searches to studies involving human subjects. We excluded conference abstracts, editorials, case reports, and review articles due to the possibility of publication bias and duplication of results.
| Data extraction and critical appraisal
We extracted data from texts, tables, and figures. Two independent investigators (JJW and JAW) reviewed each retrieved article for eligibility at the title or abstract level. The senior author (DB) resolved any discrepancies between the two investigators by discussion and consensus. Each included study was evaluated using the Cochrane Collaboration risk of bias tool 32 (see supplementary table).
| Outcomes
The primary outcome was definite or probable stent thrombosis, which was defined by the Academic Research Consortium (ARC). 33 The secondary outcomes were myocardial infarction, cardiac death, all-cause death, target lesion revascularization, and target vessel revascularization. All outcomes were extracted at the longest followup available and at 5 years of follow-up.
| Statistical analysis
Risk ratios (RRs) with 95% confidence intervals (CIs) were used for summary statistics and risk estimates to compare patients receiving either BP-DES or second-generation DP-DES. The Z test was used to derive P values. The χ 2 test was used to assess heterogeneity between studies. The I 2 statistic was used to assess total variation across studies, with values greater than 50% considered as significant heterogeneity. 32 The Mantel-Haenszel fixed-effects model was used because there was no substantial heterogeneity between studies. Risk of publication bias was assessed using funnel plots and statistical tests. 34 We performed a landmark analysis beyond 1 year of followup to evaluate late safety and efficacy outcomes. To assess the extent Figure 1 illustrates the study selection process in the present metaanalysis. We identified 1,298 references through electronic database searches. After removing duplicate studies, we retrieved 1,126 potentially relevant articles. After applying the inclusion and exclusion criteria, we included 19 RCTs 13-31 in the present meta-analysis, comprising data for 24,406 patients randomized to receive PCI with either BP-DES (n = 13,923) or second-generation DP-DES (n = 10,483). Table 1 summarizes the study characteristics of the included trials in the present meta-analysis. Patients randomized to receive BP-DES were treated with either biolimus-, sirolimus-, or everolimus-eluting stent. Patients randomized to receive second-generation DP-DES were treated with either everolimus-or zotarolimus-eluting stent.
| RESULTS
| Study selection and patient population
The RCTs were assessed to be of high quality using the Cochrane Collaboration risk of bias tool. 35 All trials had a multicenter design, with a median follow-up of 12 months. The trials clearly identified the patient population, and defined the outcomes. In four trials, 13, 21, 26, 30 the main limitation was the lack of blinding of outcomes. One trial 24 included a third comparison arm of patients randomized to receive first-generation DP-DES. Another trial 21 included a third comparison arm of patients randomized to receive bioresorbable vascular scaffolds.
We excluded data from these third comparison arms because we deemed it irrelevant to our research question. The funnel plots showed no evidence of publication bias (see supplementary figures). Table 2 summarizes the baseline characteristics of the included trials in the present meta-analysis. The enrolled patients had a weighted mean age of 64.7 ± 10.7 years for those receiving BP-DES and 64.9 ± 10.6 years for those receiving second-generation DP-DES.
| Patient and procedural characteristics
Overall, the two comparison groups had similar proportions of male patients and with diabetes mellitus, hypertension, hyperlipidemia, current smoking, previous myocardial infarction, previous procedure (PCI or coronary artery bypass grafting), clinical presentation (stable/unstable angina or non-/ST-elevation myocardial infarction), and target vessel location (left anterior descending, left circumflex, or right coronary artery) (all P > 0.05). However, the proportion of patients with previous PCI was significantly higher in those receiving BP-DES than those receiving second-generation DP-DES (26.4% vs 26.2%; P = 0.03).
| Safety and efficacy outcomes
Nineteen trials [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] BP-DES = biodegradable polymer drug-eluting stents; DAPT = dual antiplatelet therapy; DP-DES = durable polymer drug-eluting stents. Values are n/N (%) or mean ± SD; BP-DES = biodegradable drug-eluting stents; CABG = coronary artery bypass grafting; DP-DES = durable polymer drugeluting stents; LAD = left anterior descending artery; LCx = left circumflex artery; MI = myocardial infarction; NSTEMI = non-ST-elevation myocardial infarction; PCI = percutaneous coronary intervention; RCA = right coronary artery; RR = risk ratio; STEMI = ST-elevation myocardial infarction; WMD = weighted mean difference; a P value for Z test.
FIGURE 1 Flow diagram of study selection process
myocardial infarction (MI) in 24,275 patients. There was no significant difference between patients with BP-DES and those with secondgeneration DP-DES for the risk of MI (4.6% vs 4.7%; RR 0.97; 95% CI, 0.86-1.09; P = 0.59; I 2 = 0%; Figure 3 ). Nineteen trials [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] reported cardiac death in 24,279 patients. There was no significant difference between patients with BP-DES and those with second-generation DP-DES for the risk of cardiac death (2.4% vs 2.2%; RR 1.08; 95% CI, 0.92-1.28; P = 0.34; I 2 = 0%; Figure 4 ). Eighteen trials The potential chronic inflammatory stimulus of the polymer coating ultimately led to the design of BP-DES in an attempt to reduce the risk of very late ST associated with DP-DES. 5 The biodegradable nature of the polymer coating was thought to improve vascular healing response by reducing platelet aggregation and inflammatory those with DP-DES. 9 However, this benefit was not realized in our sensitivity analysis, which found no significant differences in safety and efficacy outcomes between the two stent platforms at 5 years of follow-up and on landmark analysis beyond 1 year of follow-up.
We reduced the risk of bias by combining data from RCTs only. The number of patients in each comparison arm would have increased if we used less stringent inclusion and exclusion criteria. However, the absence of significant heterogeneity across the included studies suggested that risk estimates were unlikely to change by the inclusion of observational studies. There were limitations in our meta-analysis that should be acknowledged. As with any meta-analysis, our study was based on aggregate data and, therefore, shared the possible limitations of the original studies, which in many cases compared stents with different anti-proliferative drugs, durations of DAPT, and lengths of follow-up.
We attempted to address this source of bias by performing sensitivity analyses based on these variables. The present meta-analysis summarized the results of 19 RCTs, with a median follow-up of 12 months.
Extension of follow-up beyond this time point in the original studies remains crucial to assessing late safety and efficacy outcomes of BP-DES once the polymer has been completely degraded. Further RCTs with abbreviated duration of DAPT and long-term follow-up in larger number of patients are necessary to assess the purported benefits of BP-DES.
| CONCLUSIONS
In summary, our findings demonstrated that BP-DES have similar safety and efficacy profiles to second-generation DP-DES, with comparable rates of definite or probable ST. Other safety and efficacy outcomes were equivalent between the two stent platforms.
